- Record: found
- Abstract: not found
- Article: not found
Treatment of aggressive lymphomas with anti-CD19 CAR T cells
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="P1">Adoptive immunotherapy using T cells genetically engineered
to express a chimeric
antigen receptor that targets CD19, a B-cell differentiation antigen, has demonstrated
impressive efficacy in a range of B-lymphoid malignancies. The latest results demonstrate
the potential of this approach in patients with chemotherapy-refractory diffuse large
B-cell lymphoma.
</p>